{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:57:23Z","timestamp":1792526243651,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,18]],"date-time":"2017-02-18T00:00:00Z","timestamp":1487376000000},"content-version":"vor","delay-in-days":414,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1038\/mtm.2016.58","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T16:07:05Z","timestamp":1471968425000},"page":"16058","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients"],"prefix":"10.1016","volume":"3","author":[{"given":"Vijayendra","family":"Dasari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Schuessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yide","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ambalathingal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mtm.2016.58_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.idc.2010.01.005","article-title":"Infection in organ transplantation: risk factors and evolving patterns of infection","volume":"24","author":"Fishman","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"10.1038\/mtm.2016.58_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.bmt.1705140","article-title":"Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time","volume":"36","author":"Gratwohl","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 4","key":"10.1038\/mtm.2016.58_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ajt.12093","article-title":"Introduction: Infections in solid organ transplantation","volume":"13","author":"Green","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1038\/mtm.2016.58_bib4","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/j.1600-6143.2005.00866.x","article-title":"A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients","volume":"5","author":"Humar","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1038\/mtm.2016.58_bib5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1038\/mtm.2016.58_bib6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R\u2212 kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplant"},{"key":"10.1038\/mtm.2016.58_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1038\/mtm.2016.58_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1399-3062.1999.010305.x","article-title":"Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy","volume":"1","author":"Boeckh","year":"1999","journal-title":"Transpl Infect Dis"},{"key":"10.1038\/mtm.2016.58_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1083-8791(98)90005-2","article-title":"A study of the pharmacokinetics, antiviral activity, and tolerability of oral ganciclovir for CMV prophylaxis in marrow transplantation","volume":"4","author":"Boeckh","year":"1998","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1038\/mtm.2016.58_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-6143.2009.02872.x","article-title":"Successful immunotherapy of HCMV disease using virus-specific T cells expanded from an allogeneic stem cell transplant recipient","volume":"10","author":"Hill","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1038\/mtm.2016.58_bib11","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.5","article-title":"Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation","volume":"4","author":"Holmes-Liew","year":"2015","journal-title":"Clin Transl Immunology"},{"key":"10.1038\/mtm.2016.58_bib12","first-page":"796","article-title":"Cellular immune therapy for viral infections in transplant patients","volume":"138","author":"Khanna","year":"2013","journal-title":"Indian J Med Res"},{"key":"10.1038\/mtm.2016.58_bib13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/asheducation-2013.1.342","article-title":"T-cell therapy for viral infections","volume":"2013","author":"Heslop","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1038\/mtm.2016.58_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/ehm.12.38","article-title":"T-cell therapy: a powerful tool for the management of viral infections and relapse post hematopoietic stem cell transplantation","volume":"5","author":"Kaloyannidis","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"10.1038\/mtm.2016.58_bib15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2217\/imt.15.43","article-title":"Preventing stem cell transplantation-associated viral infections using T-cell therapy","volume":"7","author":"Tzannou","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1038\/mtm.2016.58_bib16","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"10.1038\/mtm.2016.58_bib17","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"key":"10.1038\/mtm.2016.58_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/mt.2014.192","article-title":"Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells","volume":"23","author":"Melenhorst","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.58_bib19","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.58_bib20","first-page":"2736","article-title":"Generation of multivirus-specific T cells to prevent\/treat viral infections after allogeneic hematopoietic stem cell transplant","volume":"51","author":"Gerdemann","year":"2011","journal-title":"JoVE"},{"key":"10.1038\/mtm.2016.58_bib21","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1038\/cti.2014.31","article-title":"Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement","volume":"4","author":"Smith","year":"2015","journal-title":"Clin Transl Immunology"},{"key":"10.1038\/mtm.2016.58_bib22","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1038\/mtm.2016.58_bib23","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of post-transplant lymphoproliferative disease","volume":"9","author":"Bollard","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1038\/mtm.2016.58_bib24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.beha.2011.06.003","article-title":"Adoptive immunotherapy with virus-specific T cells","volume":"24","author":"Fuji","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1038\/mtm.2016.58_bib25","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1038\/cti.2014.3","article-title":"Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation","volume":"3","author":"Fern\u00e1ndez-Ruiz","year":"2014","journal-title":"Clin Transl Immunol"},{"key":"10.1038\/mtm.2016.58_bib26","doi-asserted-by":"crossref","first-page":"E42","DOI":"10.1111\/ctr.12048","article-title":"Detection of BK polyomavirus after kidney transplantation: a comparison of urine electron microscopy with plasma polymerase chain reaction","volume":"27","author":"Westervelt","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1038\/mtm.2016.58_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1038\/mtm.2016.58_bib28","first-page":"229","article-title":"Management of human cytomegalovirus infection in transplantation: validation of virologic cut-offs for preemptive therapy and immunological cut-offs for protection","volume":"34","author":"Gerna","year":"2011","journal-title":"New Microbiol"},{"key":"10.1038\/mtm.2016.58_bib29","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mtm.2016.58_bib30","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1038\/mtm.2016.58_bib31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.vaccine.2013.09.042","article-title":"Priorities for CMV vaccine development","volume":"32","author":"Krause","year":"2013","journal-title":"Vaccine"},{"key":"10.1038\/mtm.2016.58_bib32","first-page":"572","article-title":"VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection","volume":"11","author":"Schleiss","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1038\/mtm.2016.58_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2008.04.034","article-title":"A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector","volume":"377","author":"Wang","year":"2008","journal-title":"Virol"},{"key":"10.1038\/mtm.2016.58_bib34","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/14787210.5.3.449","article-title":"Vaccine strategies against human cytomegalovirus infection","volume":"5","author":"Zhong","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1038\/mtm.2016.58_bib35","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1128\/JVI.77.9.5226-5240.2003","article-title":"Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers","volume":"77","author":"Elkington","year":"2003","journal-title":"J Virol"},{"key":"10.1038\/mtm.2016.58_bib36","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","article-title":"Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments","volume":"4","author":"Gandhi","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1038\/mtm.2016.58_bib37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular responses to viral infection in humans: lessons from Epstein-Barr virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1038\/mtm.2016.58_bib38","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/JVI.01689-07","article-title":"Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy","volume":"82","author":"Leen","year":"2008","journal-title":"J Virol"}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905011730030X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905011730030X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T18:06:41Z","timestamp":1568311601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S232905011730030X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":38,"alternative-id":["S232905011730030X"],"URL":"https:\/\/doi.org\/10.1038\/mtm.2016.58","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"article-number":"16058"}}